Inventor · disambiguated record
Jean-Francois Eliaou
Also filed as: ELIAOU JEAN-FRANCOIS
5 granted patents·6 pending applications·11 citations·filing 2009–2020
74Inventor score
Files withOREGA BIOTECH5INST NAT SANTE RECH MED3BASTID JEREMY1BENSUSSAN ARMAND1INST MEDICAL DE LA SANTE ET DE LA RECH MEDICALE1
Top patents by PatentIndex Score
11 records- 0188US10662253B2Antibodies against human CD39 and use thereof for inhibiting T regulatory cells activityINST NAT SANTE RECH MED·Filed 2015·Granted May 26, 2020·5 cites·6 claims
- 0281US11685792B2Antibodies against human CD39 and use thereof for inhibiting T regulatory cells activityINST NAT SANTE RECH MED·Filed 2020·Granted Jun 27, 2023·1 cites·9 claims
- 0376US10351623B2Antagonists of IL-17 isoforms and their usesOREGA BIOTECH·Filed 2017·Granted Jul 16, 2019·3 cites·11 claims
- 0465US9676847B2IL-17 antagonist antibodiesOREGA BIOTECH·Filed 2013·Granted Jun 13, 2017·1 cites·33 claims
- 0564US9834601B2Antagonists of IL-17 isoforms and their usesOREGA BIOTECH·Filed 2013·Granted Dec 5, 2017·1 cites·6 claims
- 0659US2010303828A1Antibodies Against Human CD39 and Use Thereof for Inhibiting T Regulatory Cells ActivityINST NAT SANTE RECH MED·Filed 2009·Application pending·0 cites
- 0755US2021261686A1Antibodies against human cd39 and use thereofOREGA BIOTECH·Filed 2020·Application pending·0 cites
- 0852US2017233468A1Il-17 antagonist antibodiesOREGA BIOTECH·Filed 2017·Application pending·0 cites
- 0941US2014023650A1Methods of Treating and/or Preventing Cell Proliferation Disorders with IL-17 AntagonistsINST MEDICAL DE LA SANTE ET DE LA RECH MEDICALE·Filed 2013·Application pending·0 cites
- 1041US2013273062A1Antibodies against human cd39 and use thereofBENSUSSAN ARMAND·Filed 2011·Application pending·0 cites
- 1136US2011293629A1Methods of Treating and/or Preventing Cell Proliferation Disorders with IL-17 AntagonistsBASTID JEREMY·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jean-Francois Eliaou files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →